Quibim Awarded £2.6M to Advance Early Detection of Prostate Cancer Using AI

Published on 9 July 2025

We’re delighted to share that Quibim Ltd has been awarded £2.6 million through the NHS Cancer Programme’s Innovation Open Call, supported by SBRI Healthcare and the Accelerated Access Collaborative.

The funding will support a national evaluation of QP-Prostate®, an AI-powered software that helps radiologists detect prostate cancer earlier and more accurately from MRI scans. Prostate cancer is the most common cancer in men in the UK, with over 52,000 new cases and 12,000 deaths annually. Early detection is critical—yet currently, only 50% of cases are diagnosed at an early stage.

QP-Prostate® has shown promising results, helping radiologists detect an additional 10.6% of early-stage cancers. Over the next two years, the software will be deployed in eight NHS hospitals across England, assessing over 3,000 patients. The project will also evaluate cost-effectiveness, health inequalities, and patient perspectives on AI in cancer care.

Health Innovation West Midlands (HIWM) will play a key role in supporting the real-world evaluation and broader adoption of QP-Prostate and worked closely with the West Midlands Cancer Alliance as part of the application process.

HIWM will:

  • Help identify commissioning pathways across different ICBs to support long-term adoption.
  • Ensure key business case questions are addressed, including translating clinical outcomes into metrics relevant for commissioners.
  • Apply human factors methodologies to understand how QP-Prostate integrates into existing workflows and what changes are needed.
  • Collaborate with the Midlands Imaging Network to identify and overcome implementation barriers early.
  • Develop an insights guide to support future rollouts across the NHS.
  • Facilitate engagement through an AI Imaging Forum involving 11 ICBs, creating a safe space for shared learning and best practice.

This initiative directly supports the NHS Long Term Plan goal to diagnose 75% of cancers at stage 1 or 2 by 2028 and aligns with the Core20PLUS5 approach to reducing health inequalities.

🔗 Learn more about the NHS Cancer Programme’s £14.4 million investment in seven cutting-edge innovations here.

Quibim Awarded £2.6M to Advance Early Detection of Prostate Cancer Using AI

-


We’re delighted to share that Quibim Ltd has been awarded £2.6 million through the NHS Cancer Programme’s Innovation Open Call, supported by SBRI Healthcare and the Accelerated Access Collaborative.

The funding will support a national evaluation of QP-Prostate®, an AI-powered software that helps radiologists detect prostate cancer earlier and more accurately from MRI scans. Prostate cancer is the most common cancer in men in the UK, with over 52,000 new cases and 12,000 deaths annually. Early detection is critical—yet currently, only 50% of cases are diagnosed at an early stage.

QP-Prostate® has shown promising results, helping radiologists detect an additional 10.6% of early-stage cancers. Over the next two years, the software will be deployed in eight NHS hospitals across England, assessing over 3,000 patients. The project will also evaluate cost-effectiveness, health inequalities, and patient perspectives on AI in cancer care.

Health Innovation West Midlands (HIWM) will play a key role in supporting the real-world evaluation and broader adoption of QP-Prostate and worked closely with the West Midlands Cancer Alliance as part of the application process.

HIWM will:

  • Help identify commissioning pathways across different ICBs to support long-term adoption.
  • Ensure key business case questions are addressed, including translating clinical outcomes into metrics relevant for commissioners.
  • Apply human factors methodologies to understand how QP-Prostate integrates into existing workflows and what changes are needed.
  • Collaborate with the Midlands Imaging Network to identify and overcome implementation barriers early.
  • Develop an insights guide to support future rollouts across the NHS.
  • Facilitate engagement through an AI Imaging Forum involving 11 ICBs, creating a safe space for shared learning and best practice.

This initiative directly supports the NHS Long Term Plan goal to diagnose 75% of cancers at stage 1 or 2 by 2028 and aligns with the Core20PLUS5 approach to reducing health inequalities.

🔗 Learn more about the NHS Cancer Programme’s £14.4 million investment in seven cutting-edge innovations here.